Navigation Links
PRP therapy improves degenerative tendon disease in athletes
Date:12/1/2013

CHICAGO Ultrasound-guided delivery of platelet-rich plasma (PRP) improves functionality and reduces recovery time in athletes with degenerative disease in their tendons, according to a study being presented today at the annual meeting of the Radiological Society of North America (RSNA).

PRP therapy is a recent development in which blood is collected from the patient and then spun in a centrifuge to separate the PRP from other blood components. The PRP is then injected under ultrasound guidance into the target area, where it stimulates cellular growth and healing.

The therapy has grown popular among professional athletes from a variety of sports, who are looking to avoid surgery or prolonged recovery periods. Tiger Woods, Peyton Manning, Kobe Bryant and Rafael Nadal are just a few sports superstars who are reported to have undergone PRP therapy in recent years.

"PRP enables regeneration of the tendons and reduction of pain thanks to its regenerative and anti-inflammatory properties," said study author Alice La Marra, M.D., radiology resident at the University of L'Aquila in L'Aquila, Italy.

Dr. La Marra and colleagues recently evaluated PRP in 50 athletes who had degenerative tendinosis in the Achilles tendon, which connects the calf muscle to the heel bone, and 30 who had tendinosis in the patellar tendon, which connects the kneecap to the shin bone. Tendinosis is common in athletes and is caused by a repeating cycle of damage and repair. The Achilles and patellar tendons are common sites of tendinosis.

The patients underwent ultrasound-guided PRP every 21 days for a total of three treatments. MRI was performed before the procedures and 30 days and one year after the last treatment. The researchers used standard measures of functionality and pain to determine the severity of the tendinosis.

Patients with tendinosis of the Achilles tendon saw an overall improvement of 80 percent in pain and 53 percent in functionality after the PRP treatment. Those patients who had tendinosis in the patellar tendon saw a 75 percent improvement in pain and a 50 percent improvement in functionality.

The signal intensity on MRI, which provides a measure of tissue integrity, normalized in 90 percent of the PRP patients.

"Our study showed that in patients who underwent PRP treatments, there was an improvement of functionality, a decrease in pain and a normalization of the signal intensity seen on MRI," Dr. La Marra said. "Therefore, our experience proves that PRP infiltration may be a good therapeutic alternative for the treatment of Achilles and patellar tendinopathy in athletes."

Current treatment for degenerative diseases of these tendons is based on the severity of the lesion and the age and activity level of the person, Dr. La Marra said. Common treatment options include physical therapy, corticosteroids and surgery.

"Our study showed that PRP is the better option. Compared to the other therapies, it allows a faster and more efficient recovery," she said.

In addition, Dr. La Marra pointed out that the use of corticosteroids is risky for professional athletes, as it can result in failed drug tests.

"Considering the results obtained in recent years, we hope that the use of PRP in tendinosis becomes routine for patients who practice sports activities, even at a competitive level," she said.


'/>"/>

Contact: Linda Brooks
lbrooks@rsna.org
630-590-7762
Radiological Society of North America
Source:Eurekalert

Related medicine news :

1. KRAS gene mutation and amplification status affects sensitivity to antifolate therapy
2. Antibody therapy prevents gastrointestinal damage following radiation exposure in mice
3. Chemotherapy proves life-saving for some leukemia patients who fail induction therapy
4. Immunotherapy for elderly cancer patients finds new promise in drug combination
5. Therapy exploits addiction of leukemia cells
6. Intensity Modulated Radiation Therapy optimal for localized prostate cancer
7. Adding drug to standard chemotherapy provides no survival benefit for older lung cancer patients
8. Study Casts Doubt on Value of Pricey Prostate Cancer Therapy
9. 19th century therapy for Parkinsons disease may help patients today
10. New Psoriasis Drugs Not Much Better Than Standard Therapy, Study Finds
11. Xenotransplantation as a therapy for type 1 diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... Back Pain Centers ... back pain with a reputable physician in their area, announces the launch of a ... information for patients who are looking for reputable physicians to help them with back ...
(Date:4/25/2017)... ... , ... There is no better place in South Florida to undergo two ... May issue of Consumer Reports focused on heart health. , The magazine gave ... after coronary bypass and aortic valve replacement procedures. , Consumer Reports rated ...
(Date:4/24/2017)... Nashville, TN (PRWEB) , ... April 24, 2017 , ... ... electrifying fans and transforming the quarterback position. The former overall number one pick in ... his professional football career. He holds the record for the most career rushing yards ...
(Date:4/24/2017)... , ... April 24, 2017 , ... The bar for ... those unreal icons inhabiting the rarified air of pop and film stardom.(1) Not to ... anyone snapping pictures: the smile. Grins now run the gamut from being encrusted with ...
(Date:4/24/2017)... ... ... The John P. McGovern Museum of Health and Medical Science is now partnered with ... share results with their physicians. Members and guests can sign up for its free ... Dr. David Eagleman, formerly at Baylor College of Medicine and now at Stanford University, ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , April 19, 2017 ... an immune response in pets such as canine, ... are of various types such as Attenuated Live ... Vaccines, DNA Vaccines and Recombinant Vaccines. Attenuated live ... virus or bacteria, which have been weakend under ...
(Date:4/18/2017)...  Cardinal Health (NYSE: CAH ) today ... per share (EPS) guidance and providing a preliminary view ... with this morning,s announcement of the planned acquisition of ... businesses. Cardinal Health now believes that fiscal ... the bottom of its previous guidance range of $5.35 ...
(Date:4/18/2017)... 18, 2017  Astute Medical, Inc., developer of biomarkers ... be presented at the 2017 National Kidney Foundation (NKF) ... continues through April 22. Physicians will present data on ... assess risk for acute kidney injury (AKI) during the ... Elevated levels of TIMP-2 and IGFBP-7 ...
Breaking Medicine Technology: